Last quarter (Q4 2022), OncoSil Medical Ltd's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, OncoSil Medical Ltd's net income was AU$―. See OncoSil Medical Ltd’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	-	AU$ 231.79K	AU$ 213.07K	-	-	-
Cost of Revenue	-	AU$ 972.47K	AU$ 961.02K	-	-	-
Gross Profit	-	AU$ -740.68K	AU$ -747.95K	-	-	-
Operating Expense	-	AU$ 10.80M	AU$ 11.06M	AU$ 7.36M	AU$ 12.41M	AU$ 13.80M
Operating Income	-	AU$ -11.54M	AU$ -11.81M	AU$ -7.36M	AU$ -12.41M	AU$ -13.80M
Net Non Operating Interest Income Expense	-	AU$ -9.49K	AU$ 66.74K	AU$ 93.80K	AU$ 204.11K	AU$ 144.76K
Other Income Expense	-	AU$ 692.11K	AU$ 1.13M	AU$ 2.85M	AU$ 3.64M	AU$ 5.12M
Pretax Income	-	AU$ -10.73M	AU$ -10.43M	AU$ -4.26M	AU$ -8.57M	AU$ -8.54M
Tax Provision	-	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	AU$ -10.73M	AU$ -10.43M	AU$ -4.26M	AU$ -8.57M	AU$ -8.54M
Basic EPS	-	AU$ -0.01	AU$ -0.01	AU$ >-0.01	AU$ -0.01	-
Diluted EPS	-	AU$ -0.01	AU$ -0.01	AU$ >-0.01	AU$ -0.01	-
Basic Average Shares	-	AU$ 997.88M	AU$ 828.13M	AU$ 664.23M	AU$ 641.02M	-
Diluted Average Shares	-	AU$ 997.88M	AU$ 828.13M	AU$ 664.23M	AU$ 641.02M	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	-	AU$ -10.73M	AU$ -10.43M	AU$ -4.26M	AU$ -8.57M	AU$ -8.54M
Normalized Income	-	AU$ -10.73M	AU$ -10.43M	AU$ -4.26M	AU$ -8.57M	AU$ -8.54M
Interest Expense	-	-	AU$ 1.08K	AU$ 861.00	-	-
EBIT	-	AU$ -11.54M	AU$ -10.43M	AU$ -4.26M	AU$ -12.41M	AU$ -13.80M
EBITDA	-	AU$ -11.41M	AU$ -10.25M	AU$ -4.11M	AU$ -12.41M	AU$ -13.76M

Currency in AUD

OncoSil Medical Ltd Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing